Core Viewpoint - The agreement between Beijing JACOS and AstraZeneca for the development and commercialization of the pan-KRAS inhibitor JAB-23E73 represents a significant collaboration in the pharmaceutical industry, with potential financial benefits for Beijing JACOS through upfront and milestone payments [1] Group 1: Agreement Details - Beijing JACOS has entered into a licensing and collaboration agreement with AstraZeneca for the pan-KRAS inhibitor JAB-23E73 [1] - AstraZeneca is granted exclusive rights to research, develop, register, manufacture, and commercialize JAB-23E73 globally, excluding mainland China [1] - The collaboration will involve joint development and commercialization in mainland China, with both parties adhering to a governance framework outlined in the agreement [1] Group 2: Financial Implications - Beijing JACOS is entitled to receive an upfront payment of $100 million from AstraZeneca [1] - Additional potential milestone payments could total up to $1.915 billion, contingent upon achieving specific development, regulatory, and commercial milestones [1] - Upon successful commercialization of the licensed product, Beijing JACOS will receive tiered royalties based on the net sales of the product [1]
加科思-B附属与阿斯利康订立许可与合作协议，以开发及商业化泛KRAS抑制剂JAB-23E73